000538 云南白药
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入11,602,5977.02%41,186,99940,033,30139,111,29236,488,373
减:营业总成本9,475,4108.28%36,210,22435,206,79735,082,75032,087,168
    其中:营业成本8,048,3638.46%29,032,92328,864,76628,744,51826,883,485
               财务费用11,390-223.74%(46,890)(155,555)(259,244)(342,878)
               资产减值损失(6,621)-71.35%(258,372)(91,231)(58,128)(664,339)
公允价值变动收益16,376-60.02%110,489136,837123,566(619,903)
投资收益242,9699.17%1,042,986776,937779,011868,198
    其中:对联营企业和合营企业的投资收益251,7627.94%989,142774,280628,532732,233
营业利润2,361,5854.71%6,038,8955,711,6224,830,5063,371,279
利润总额2,360,8794.65%6,043,2715,684,7204,818,0123,377,002
减:所得税费用330,2980.56%853,330917,647695,451536,593
净利润2,030,5815.35%5,189,9414,767,0724,122,5612,840,410
减:非控股权益(6,726)-5.65%36,45417,65728,779(160,716)
股东净利润2,037,3075.31%5,153,4874,749,4154,093,7823,001,126

市场价值指针
每股收益 (元) *1.1405.56%2.8902.6602.2901.900
每股派息 (元) *----2.6022.3982.0771.520
每股净资产 (元) *23.5933.26%22.44321.76422.19421.428
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容